The U.S. Food and Drug Administration approved a new antibacterial drug Dalvance (dalbavancin) for use in the treatment of adult skin infections. Dalbavancin is intended to treat Acute Bacterial Skin and Skin Structure Infections (ABSSSI). ABSSSI is caused by certain susceptible bacteria like Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains) and Streptococcus pyogenes. The […]